Lista de obras - Günter Niegisch - Dominio Público Uruguay

A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.

artículo científico publicado en 2018

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

artículo científico publicado en 2014

Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane

artículo científico publicado en 2006

Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma

artículo científico publicado en 2017

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

artículo científico publicado en 2017

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

artículo científico publicado en 2017

Canonical Notch signalling is inactive in urothelial carcinoma.

artículo científico publicado en 2014

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers

artículo científico publicado en 2012

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

scientific article published on 03 January 2017

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

artículo científico publicado en 2015

Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy

artículo científico publicado en 2014

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1

artículo científico publicado en 2020

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.

artículo científico publicado en 2018

Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion

artículo científico publicado en 2018

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

artículo científico publicado en 2014

Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases

scientific article published on 06 November 2019

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma

artículo científico publicado en 2014

Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]

scientific article published on 28 November 2018

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

artículo científico publicado en 2018

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.

artículo científico publicado en 2017

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.

artículo científico publicado en 2016

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines

scientific article published on 09 October 2019

Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?

scientific article published on 01 December 2018

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells

artículo científico publicado en 2021

Effects of novel HDAC inhibitors on urothelial carcinoma cells.

artículo científico publicado en 2018

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database

scientific article published on 13 July 2019

Epigenetic Treatment Options in Urothelial Carcinoma

artículo científico publicado en 2018

Epigenetics of urothelial carcinoma.

artículo científico publicado en 2015

Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

scientific article published on 25 March 2020

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

artículo científico publicado en 2016

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. ⬇️

artículo científico publicado en 2019

HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.

artículo científico publicado en 2017

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma.

artículo científico publicado en 2013

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.

artículo científico publicado en 2014

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

artículo científico publicado en 2016

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).

artículo científico publicado en 2017

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

scientific article published on 01 November 2019

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design

artículo científico publicado en 2013

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma

scientific article published on 04 September 2018

Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.

artículo científico publicado en 2014

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

scientific article published on 11 July 2019

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

artículo científico publicado en 2016

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines

artículo científico publicado en 2020

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

artículo científico publicado en 2017

Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.

artículo científico publicado en 2014

MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer.

artículo científico publicado en 2014

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer

artículo científico publicado en 2020

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials

scientific article published on 07 September 2018

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.

artículo científico publicado en 2018

Multiple mechanisms mediate resistance to sorafenib in urothelial cancer

artículo científico publicado en 2014

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

artículo científico publicado en 2013

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

artículo científico publicado en 2016

Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse

scientific article published on 14 January 2019

Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.

artículo científico publicado en 2013

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

artículo científico

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer

artículo científico publicado en 2016

Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC).

artículo científico publicado en 2014

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

artículo científico publicado en 2015

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

artículo científico publicado en 2019

Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).

artículo científico publicado en 2011

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression

publication published on 27 May 2022

Quality control in the implementation of new surgical procedures: Da Vinci robot-assisted systems

artículo científico publicado en 2011

Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy

artículo científico publicado en 2016

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators

artículo científico publicado en 2017

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

artículo científico publicado en 2010

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

artículo científico publicado en 2017

Robot-assisted radical cystectomy. Pilot study for the prospective evaluation of perioperative parameters compared to open radical cystectomy

artículo científico publicado en 2011

Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk.

artículo científico publicado en 2012

Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.

artículo científico publicado en 2010

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).

artículo científico publicado en 2015

Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?

artículo científico publicado en 2019

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.

artículo científico publicado en 2015

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma

artículo científico publicado en 2013

Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma

artículo científico publicado en 2014

Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?

artículo científico publicado en 2017

Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.

artículo científico publicado en 2017

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer

artículo científico publicado en 2019

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.

artículo científico publicado en 2016

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells

artículo científico publicado en 2015

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

artículo científico publicado en 2013

Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors.

artículo científico publicado en 2015

Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene

scientific article published on 03 September 2011

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines

artículo científico publicado en 2017

Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

artículo científico publicado en 2017

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival

scientific article published on 20 December 2016

Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?

artículo científico publicado en 2011

[Chemotherapy for urothelial cancer of the bladder--update 2012]

scientific article published on 29 November 2012

[Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options]

artículo científico publicado en 2015

[Personalised medicine in urothelial bladder cancer]

scientific article published on 13 June 2019

[Radical cystectomy and urinary diversion-what is important ?]

artículo científico publicado en 2018

[Robot-assisted radical cystectomy: do we actually need a robot?]

artículo científico publicado en 2012

[Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?].

artículo científico publicado en 2010

[Urothelial cancer: update on systemic treatment options]

artículo científico publicado en 2017

Lista de obras de Günter Niegisch

A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane

Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Canonical Notch signalling is inactive in urothelial carcinoma.

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.

Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma

Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines

Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells

Effects of novel HDAC inhibitors on urothelial carcinoma cells.

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database

Epigenetic Treatment Options in Urothelial Carcinoma

Epigenetics of urothelial carcinoma.

Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. ⬇️

HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma.

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma

Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.

MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer.

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.

Multiple mechanisms mediate resistance to sorafenib in urothelial cancer

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse

Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer

Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC).

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression

Quality control in the implementation of new surgical procedures: Da Vinci robot-assisted systems

Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Robot-assisted radical cystectomy. Pilot study for the prospective evaluation of perioperative parameters compared to open radical cystectomy

Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk.

Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).

Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma

Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma

Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?

Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.